Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Clinical trial NCT02199184 · COMPLETED

Trial details

NCT number: NCT02199184
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

AIDS-Related Burkitt Lymphoma Atypical Burkitt/Burkitt-Like Lymphoma High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recurrent Acute Lymphoblastic Leukemia Recurrent Burkitt Lymphoma Refractory Acute Lymphoblastic Leukemia Refractory Burkitt Lymphoma

Start date: 2015-01-14
Primary completion: 2023-02-17
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.